NewAmsterdam Pharma initiated with a Buy at Stifel

Stifel initiated coverage of NewAmsterdam Pharma (NAMS) with a Buy rating and $44 price target NewAmsterdam sets up as “a unique, late-stage cardiovascular-focused company” with a near-term path to regulatory filings and a cardiovascular outcomes trial that “very likely differentiates obicetrapib” within the large, growing lipid-lowering market, the analyst tells investors. There is “a significant amount of data/literature” supporting that obicetrapib and the PREVAIL trial are “fundamentally different” and even with “conservative commercial assumptions per docs,” the firm sees the potential for significant upside to shares.